PHARNEXT-SAS
Pharnext SAS today announced its collaboration with OrphanDev, a dedicated platform offering support in regulatory, methodology and logistics for rare diseases. OrphanDev’s main mission is to accelerate the development of orphan drugs. This collaboration is related to the International pivotal Phase 3 trial of Pharnext’s investigational Pleodrug, PXT-3003, for the treatment of CMT 1A.
PLEO-CMT aims at recruiting 300 patients in 27 centers both in Europe and the United States. For the European part of the trial (18 centers spread over Germany, Belgium, Spain, France, the UK and the Netherlands), OrphanDev will play a critical role in the dissemination and availability of practical and logistical information related to the trial, notably via its website: www.orphan-dev.org .
Pharnext and OrphanDev had already collaborated on 3 studies related to CMT 1A: PXT-3003 Phase2 study, a meta-analysis and a prospective study (biomarkers).
About PXT-3003
PXT-3003 is a novel oral fixed-low dose
combination of (RS)-baclofen, naltrexone hydrochloride and D-sorbitol
which has been developed via Pharnext Pleotherapy R&D platform.
About PLEO-CMT
PLEO-CMT is an International pivotal,
multi-center, randomized, double blind, placebo-controlled, three-arm
Phase 3 study which will enroll patients
aged 16 to 65 with mild to
moderate CMT1A. Over 15 months, Pharnext will compare in parallel groups
the efficacy and safety of two orally administered dosage variations of
PXT-3003 versus
placebo. Efficacy will be assessed through one
primary endpoint: change in the ONLS score at 12 and 15 months of
treatment to measure improvement of patients’ disability with PXT-3003.
Additional secondary outcome measures will be assessed including
functional and electrophysiological endpoints. A nine month follow-up
study is planned thereafter, where all patients who will have completed
the first 15 months and agreed, will receive a dose of the active
product (patients who received placebo will be treated randomly with
PXT-3003 dose 1 or 2).
About CMT 1A
Charcot-Marie-Tooth (CMT) disease encompasses a
heterogeneous group of inherited, progressive, chronic peripheral
neuropathies. CMT type 1A (CMT 1A), the most common type of CMT, is an
orphan disease affecting at least 125,000 people in Europe and the U.S.
The genetic mutation responsible for CMT 1A is a duplication of the PMP
22 gene coding for a peripheral myelin protein. Overexpression of this
gene causes degradation of the neuronal sheath (myelin) responsible for
nerve dysfunction, followed by loss of nerve conduction. As a result of
peripheral nerve degradation, patients suffer from progressive muscle
atrophy of legs and arms causing walking, running, balance problems and
abnormal hand functioning. CMT 1A patients end up in wheelchairs in at
least 5% of cases. They might also suffer from mild to moderate
sensitive disorders. First symptoms usually appear during adolescence
and will progressively evolve through patients’ life.
To date, no
curative or symptomatic medications have been approved and treatment
consists of supportive care such as orthotics, leg braces, physical and
occupational therapy or surgery.
About OrphanDev
OrphanDev is an academic platform at the
heart of rare diseases, close to research teams, clinicians, industry
professionals and patient organizations. It offers its scientific,
regulatory and methodological expertise in the development of drugs for
rare diseases. OrphanDev assists its partners, particularly for Orphan
Drug Designation applications, the recruitment of patients for clinical
trials, and European projects. OrphanDev is a public platform linked to
the University of Aix Marseille (France) and the Timone Institute of
Neurosciences based in Marseille. OrphanDev is a component of the F-CRIN
infrastructure (French Clinical Research Network) which had mission to
reinforce the visibility and the competitiveness of French clinical
research.
For further information, visit http://orphan-dev.org
About Pharnext
Pharnext is an advanced clinical stage
biopharmaceutical company developing novel therapeutics that
simultaneously target multiple key disease pathways for severe orphan
and common neurological disorders. The proprietary research and
development platform of Pharnext, based on network pharmacology, is
applicable to a broad spectrum of diseases and allows the rapid
development of “pleodrugs”, synergistic combinations of repositioned
drugs with established safety profiles. The company’s two lead pleodrugs
are PXT-3003 for the treatment of orphan disease Charcot Marie Tooth
type 1A (Phase 3 clinical trial initiated) and PXT-864 for Alzheimer’s
disease (Phase 2 clinical trial ongoing) and other neurologic
indications (including Parkinson’s disease and amyotrophic lateral
sclerosis).
For further information, visit www.pharnext.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160125006262/en/
Contact:
Pharnext Contact
Daniel Cohen, M.D., Ph.D.
Chairman and
Chief Executive Officer
medical@pharnext.com
or
Media
Contact
ALIZE RP
Florence Portejoie and Caroline Carmagnol
Tél :
01 44 54 36 64
pharnext@alizerp.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom